TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04693585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSSSAGE - live
Description: mHealth education and social support intervention, synchronous via call

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSSSAGE - live
Description: mHealth education and social support intervention, synchronous via call

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSSSAGE - asynchronous
Description: mHealth education and social support intervention, asynchronous via text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSSSAGE - asynchronous
Description: mHealth education and social support intervention, asynchronous via text
Study: NCT05387629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Nursing students will be trained through social media.
Study: NCT06432959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy, Positive Affect Promoting Activities
Description: The specific activities that constitute the positive affect interventions will be determined by the therapist and participant collaboratively. Some examples of positive affect promoting activities are:~* Watch videos of animals and babies~* Eat a piece of candy~* Recall and describe a past positive experience~* Describe the positive attributes of the participant~* Engage in gratitude practice~* Do something nice for someone~The in-session positive affect activities will last approximately five minutes. For the first four weeks, the positive affect activities will be completed at the beginning of the session. After that, therapists will look for opportunities to incorporate positive affect activities at stuck points or before learning a new skill in-session. Additionally, therapists will work with participants to identify ways in which the participants can incorporate positive affect activities into their lives between sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Meet with treatment providers individually or in group to learn skills to address symptoms associated with depression and emotion dysregulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Meet with treatment providers individually or in group to learn skills to address symptoms associated with depression and emotion dysregulation
Study: NCT06464445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic iTBS
Description: iTBS protocol with monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of resting motor threshold (rMT)~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic iTBS
Description: iTBS protocol with biphasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic-Long iTBS
Description: iTBS protocol with long monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds
Study: NCT05695885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS
Description: behavioral counseling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Services as usual (SAU)
Description: behavioral counseling normally provided
Study: NCT05405335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Positioning Maneuver
Description: intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
Study: NCT06723652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1918
Description: six administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1918 placebo
Description: SHR-1918 placebo three administration+SHR-1918 three administration
Study: NCT06722963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
Study: NCT06724471

Intervention type: DEVICE
Intervention: Human ovarian tissue cryopreservation using thermosoldered or screwed cryovials
Description: Human ovarian tissue Cryopreservation: immediately after cyst resection, pericystic ovarian cortex will be cut into 1mm3 fragments and cryopreserved in screwed or thermosoldered cryovials using a slow programmable freezing device (Nano Digitcool, Cryo Bio System).

Intervention type: DEVICE
Intervention: Human ovarian tissue cryopreservation using thermosoldered or screwed cryovials
Description: Human ovarian tissue Cryopreservation: immediately after cyst resection, pericystic ovarian cortex will be cut into 1mm3 fragments and cryopreserved in screwed or thermosoldered cryovials using a slow programmable freezing device (Nano Digitcool, Cryo Bio System).
Study: NCT06722209

Intervention type: OTHER
Group type: OTHER
Intervention: polyethylene glycol (Protocol I)
Description: Intestinal preparation protocol with polyethylene glycol (Protocol I)

Intervention type: OTHER
Group type: OTHER
Intervention: polyethylene glycol (Protocol I)
Description: Intestinal preparation protocol with polyethylene glycol (Protocol I)
Study: NCT06723405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVO301
Description: Intravenous EVO301

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06723067

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable wireless breast pump
Description: As above

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable wireless breast pump
Description: As above
Study: NCT06724159

Intervention type: DRUG
Intervention: darolutamide
Description: Darolutamide in combination with androgen deprivation therapy and docetaxel. Following the posology and administration details of its marketing authorization and standard clinical practice

Intervention type: DRUG
Intervention: Nivolumab monotherapy
Description: Adjuvant nivolumab following after surgical removal of urothelial carcinoma. Following the posology and administration details of its marketing authorization and standard clinical practice

Intervention type: DRUG
Intervention: enfortumab vedotin
Description: Following the posology and administration details of its marketing authorization and standard clinical practice
Study: NCT06722391

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (Sensory)
Description: Group will receive Electrical Stimulation up to sensory level

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (Sensory)
Description: Group will receive Electrical Stimulation up to sensory level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Group will receive Electrical Stimulation up to maximum tolerable level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Group will receive Electrical Stimulation up to maximum tolerable level

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Group will receive exercise training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Group will receive exercise training.
Study: NCT06722820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPH-5
Description: LPH-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPH-5
Description: LPH-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPH-5
Description: LPH-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPH-5
Description: LPH-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPH-5
Description: LPH-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPH-5
Description: LPH-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06393972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG BID
Description: Tofacitinib 5 MG BID
Study: NCT06722196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical amiodarone
Description: amiodarone soaked patch placed on the left atrial roof at the end of surgery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline solution patch
Description: saline solution soaked patch placed on left atrial roof at the end of surgery
Study: NCT06724783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen membrane
Description: Implant placement with simultaneous GBR covered with a collagen membrane
Study: NCT05582772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GA+M Intervention
Description: Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RSM intervention
Description: Telephone-based, symptom management of patients with cancer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GA+RSM intervention
Description: Combining a geriatric assessment and remote symptom control
Study: NCT05022966

Intervention type: OTHER
Intervention: No intervention
Description: Individuals did not received any intervention.
Study: NCT05451771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet, 200 mg
Description: 200 mg oral tablet daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FISH assay
Description: Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FISH assay
Description: Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FISH assay
Description: Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FISH assay
Description: Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet, 400 mg
Description: 400 mg oral tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet, 400 mg
Description: 400 mg oral tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet, 400 mg
Description: 400 mg oral tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral, 10 mg
Description: 10 mg oral tablet weekly
Study: NCT04751812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-pain multimodal anesthesia with opioids
Description: Paracetamol, Etoricoxib, Oxycodone, Ondansetron po. Betamethasone 4 mg iv.~Anesthesia:~As standard + bolus esketamine 0.25 mg/kg iv + Clonidine 1 µg/kg i.v.~Postoperative pain treatment:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v.
Study: NCT06724783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane
Description: Implant placement with simultaneous GBR covered with a collagen membrane
Study: NCT05451771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral, 20 mg
Description: 20 mg oral tablet weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral, 20 mg
Description: 20 mg oral tablet weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab Injection
Description: Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib
Description: Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax MTD with Dexamethasone
Description: Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
Study: NCT05748340

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral cleft lip repair
Description: Surgical repair unilateral cleft lip

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral cleft lip repair
Description: Surgical repair unilateral cleft lip

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral cleft lip repair
Description: Surgical repair unilateral cleft lip
Study: NCT05457569

Intervention type: OTHER
Intervention: Focus group (FC) - WP1
Description: 3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk

Intervention type: OTHER
Intervention: Focus group (FC) - WP1
Description: 3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk

Intervention type: OTHER
Intervention: Focus group (FC) - WP1
Description: 3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk

Intervention type: OTHER
Intervention: Focus group (FC) - WP1
Description: 3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk

Intervention type: OTHER
Intervention: Child Neurodevelopment Questionnaires - WP2
Description: during the 4th month of corrected infant age

Intervention type: OTHER
Intervention: Evaluation of compliance for the acquired skills in terms of development support - WP2
Description: during the 4th month of corrected infant age

Intervention type: OTHER
Intervention: Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2
Description: at the end of the study

Intervention type: OTHER
Intervention: 4 Focus Group (FC) - WP2
Description: * Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice

Intervention type: OTHER
Intervention: 4 Focus Group (FC) - WP2
Description: * Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice

Intervention type: OTHER
Intervention: 4 Focus Group (FC) - WP2
Description: * Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice
Study: NCT04847934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: distraction methods
Description: distraction methods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: distraction methods
Description: distraction methods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: distraction methods
Description: distraction methods
Study: NCT05981027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan bent leg raise technique
Description: In this study, while the participant was lying on his back on a high bed, the physiotherapist sat on the lateral side of the leg to be treated, placing the popliteal fossa of the participant's knee on his shoulder. The hip and knee of the leg to be stretched were placed in 90° flexion. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with his leg and then relax. At this relaxation point, the physiotherapist pushed the flexed knee as far as possible in the direction of the ipsilateral shoulder in a painless range.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching exercise
Description: The participant lay on a stretcher in the supine position with his back straight. The physiotherapist placed the participant's leg on his shoulder with the knee in full extension and supported by the ankle and flexed the hip as much as possible until a tension was felt in the posterior thigh. This position was maintained for 30 seconds.
Study: NCT06071650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise to a Heart Rate (HR) Zone
Description: Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
Study: NCT05500313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypno-breastfeeding Education
Description: The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Standart Breastfeeding Education
Description: The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
Study: NCT04851288

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a biochemically modified form of ubiquinol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule contains inert excipient and is identical in appearance
Study: NCT05941156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD56 CAR T
Description: CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
Study: NCT05292560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in positivity
Description: The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Training in positivity
Description: The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
Study: NCT05409027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62
Description: SPI-62 is supplied as 1 mg tablets for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortisone-d8
Description: Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion